​

Palisade Bio (PALI) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

PALI Stock Forecast

Palisade Bio (PALI) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $4.50, with a high of $7.00 and a low of $2.00. This represents a 287.93% increase from the last price of $1.16.

$1 $2 $3 $4 $5 $6 $7 High: $7 Avg: $4.5 Low: $2 Last Closed Price: $1.16

PALI Stock Rating

Palisade Bio stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

PALI Price Target Upside V Benchmarks

TypeNameUpside
StockPalisade Bio287.93%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$4.50
Last Closing Price$1.16$1.16$1.16
Upside/Downside--287.93%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2637---10
Oct, 2617---8
Sep, 2617---8
Aug, 2627---9
Jul, 2626---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 30, 2026Oppenheimer$7.00$2.23213.90%503.45%
Nov 17, 2023Naz RahmanMaxim Group$1.50$9.07-83.46%29.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2026OppenheimerOutperformOutperformhold
Oct 13, 2026H.C. WainwrightBuyBuyhold
Oct 08, 2026Raymond JamesOutperforminitialise
Jul 23, 2026OppenheimerOutperforminitialise
Jun 30, 2026H.C. WainwrightBuyBuyhold
Apr 08, 2026Wolfe ResearchOutperforminitialise
Mar 26, 2026H.C. WainwrightBuyinitialise
Jan 09, 2026B. RileyBuyinitialise
Dec 29, 2025Piper SandlerOverweightinitialise
Nov 11, 2025CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-30 $-24 $-18 $-12 $-6 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-27.01$-10.19$-0.30---
Avg Forecast$-28.14$-11.97$-3.66$-3.72$-4.79$-5.85
High Forecast$-28.14$-11.31$-2.27$-1.23$-2.29$-5.85
Low Forecast$-28.14$-12.62$-5.04$-6.21$-8.46$-5.85
Surprise %-4.02%-14.87%-91.80%---

Revenue Forecast

$0 $10M $20M $30M $40M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$250.00K-----
Avg Forecast$250.00K$8.21M$12.15M$27.87M$47.71M$48.23K
High Forecast$250.00K$8.21M$12.15M$27.87M$47.71M$48.23K
Low Forecast$250.00K$8.21M$12.15M$27.87M$47.71M$48.23K
Surprise %------

Net Income Forecast

$-20M $-16M $-12M $-8M $-4M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-12.30M$-14.44M$-16.78M---
Avg Forecast$-12.83M$-5.46M$-1.67M$-1.70M$-2.45M$-2.67M
High Forecast$-12.83M$-5.16M$-1.04M$-560.90K$-1.04M$-2.67M
Low Forecast$-12.83M$-5.76M$-2.30M$-2.83M$-3.86M$-2.67M
Surprise %-4.16%164.61%906.82%---

PALI Forecast FAQ

Is Palisade Bio stock a buy?

Palisade Bio stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Palisade Bio is a favorable investment for most analysts.

What is Palisade Bio's price target?

Palisade Bio's price target, set by 4 Wall Street analysts, averages $4.5 over the next 12 months. The price target range spans from $2 at the low end to $7 at the high end, suggesting a potential 287.93% change from the previous closing price of $1.16.

How does Palisade Bio stock forecast compare to its benchmarks?

Palisade Bio's stock forecast shows a 287.93% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Palisade Bio over the past three months?

  • November 2026: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Palisade Bio’s EPS forecast?

Palisade Bio's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.72, marking a 1140.00% increase from the reported $-0.3 in 2025. Estimates for the following years are $-4.79 in 2027, and $-5.85 in 2028.

What is Palisade Bio’s revenue forecast?

Palisade Bio's average annual revenue forecast for its fiscal year ending in December 2026 is $27.87M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $47.71M, and $48.23K for 2028.

What is Palisade Bio’s net income forecast?

Palisade Bio's net income forecast for the fiscal year ending in December 2026 stands at $-1.696M, representing a -89.89% decrease from the reported $-16.781M in 2025. Projections indicate $-2.45M in 2027, and $-2.665M in 2028.